Tags: Diabetes | Type 2 diabetes | hemoglobin A1c levels | blood sugar levels | dulaglutide | diabetes drugs

New Diabetes Drug Shows Effectiveness

Tuesday, 16 Apr 2013 12:15 PM

Eli Lilly and Co said two additional late-stage studies testing its experimental diabetes drug dulaglutide met the main goal of reducing hemoglobin A1c levels, a measure of blood sugar.
 
Along with positive results from three other late-stage trials announced in October, the data will support a marketing application for dulaglutide, Lilly said in a statement.
 
In the study named AWARD 2, the company said a 1.5 mg dose of its drug proved superior to Sanofi's Lantus, at 52 weeks in Type 2 diabetes patients, who are already on two other diabetes drugs, metformin and glimeperide.
 
Dulaglutide also trumped insulin lispro, in combination with Lantus, at 26 weeks of treatment in a study dubbed as AWARD 4, Lilly said.
 
The company said the most frequently reported adverse events were gastrointestinal.
 
In October, Lilly reported positive results of the other three studies in which dulaglutide was compared with other diabetes medications.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved